Company Interview / Cyclopharm Wins Unprecedented US Clinical Backing

Key points:

Technegas named as preferred lung ventilation agent in US nuclear medicine guidelines Cyclopharm grows presence at major US medical institutions Investments made in US sales force and inventory to support expansion Outside the US, Technegas holds about 85% market share where available

Cyclopharm has achieved a significant milestone in the adoption of its proprietary lung imaging technology, Technegas, in the US market. James McBrayer states it is unprecedented for a radiopharmaceutical product to be specifically named in international guidelines, with Technegas now recognised as the preferred ventilation agent for functional lung imaging by the Society of Nuclear Medicine and the American College of Nuclear Medicine. McBrayer emphasises that clinical guidelines play a substantial role in shaping practice and views the endorsement as pivotal for expanding market share in the US, following recent FDA approval.

McBrayer highlights Technegas as the agent of choice wherever it is established, mainly used in diagnosing pulmonary embolism and applied in a range of respiratory conditions, including COPD, asthma, and lung transplants. Cyclopharm has already secured traction at numerous prominent US institutions, such as Stanford, Mayo Clinic, and New York Presbyterian, and anticipates accelerating institutional adoption across the US nuclear medicine sector.

Cyclopharm (ASX:CYC) has invested heavily in its US sales infrastructure, with inventory ready for deployment and a new sales force to match the growing demand. McBrayer indicates that, outside the US, Technegas commands 85% market share, and the recent guideline endorsement will further drive adoption and expand applications for patients globally.